stockrowNovartis AG
NVS Healthcare Drug Manufacturers General
Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.
- Revenue
- +4.67%
- EPS
- −69.1%
- Free cash flow
- −17.8%
- Total debt
- +53.9%
Quarter to September 2026, against a year earlier
Follow NVS
Alert me
Novartis AG (NVS) Revenue growth
Novartis AG's revenue growth over the twelve months to 30 September 2026 was 1.76%, down 7.8 percentage points from fiscal 2025 (9.57%). Over the past ten years it has ranged from −17.8% (fiscal 2022) to 10.9% (fiscal 2024); the current reading is higher than 91% of that period. That is below the Drug Manufacturers General industry median of 6.72% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 9.57% | (1.28) |
| FY2024 | 10.9% | 3.49 |
| FY2023 | 7.36% | 25.17 |
| FY2022 | −17.8% | (23.78) |
| FY2021 | 5.97% | 3.46 |
| FY2020 | 2.51% | (3.08) |
| FY2019 | 5.59% | 13.64 |
| FY2018 | −8.05% | (9.46) |
| FY2017 | 1.41% | 3.30 |
| FY2016 | −1.89% | 4.16 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 4.67% | 3.89 |
| Jun 2026 | 0.78% | 1.48 |
| Mar 2026 | −0.70% | (2.93) |
| Dec 2025 | 2.23% | (6.77) |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| NVO Novo Nordisk A/S compare | 13.2% |
| ABBV AbbVie Inc. compare | 10.7% |
| AMGN Amgen Inc. compare | 8.15% |
| JNJ Johnson & Johnson compare | 7.80% |
| AZN AstraZeneca PLC compare | 7.32% |
| GILD Gilead Sciences, Inc. compare | 6.54% |
| MRK Merck & Co., Inc. compare | 4.89% |
| NVS Novartis AG | 1.76% |
| PFE Pfizer Inc. compare | 1.34% |
| Drug Manufacturers General industry median | 6.72% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on NVS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement